First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial
机构:[1]Tongji Univ, Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China[2]Hunan Canc Hosp, Med Oncol, Changsha, Hunan, Peoples R China[3]Harbin Med Univ, Canc Hosp, Med Oncol, Harbin, Heilongjiang, Peoples R China[4]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Oncol, Guangzhou, Guangdong, Peoples R China[5]Liaoning Canc Hosp & Inst, Med Oncol, Shenyang, Liaoning, Peoples R China[6]Cent S Univ, Xiangya Hosp, Med Oncol, Changsha, Hunan, Peoples R China[7]Jiangsu Canc Hosp, Med Oncol, Nanjing, Jiangsu, Peoples R China[8]Peking Univ, Canc Hosp, Med Oncol, Beijing, Peoples R China[9]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Med Oncol, Wuhan, Hubei, Peoples R China[10]Zhejiang Canc Hosp, Med Oncol, Hangzhou, Zhejiang, Peoples R China[11]Guangxi Med Univ, Affiliated Tumor Hosp, Med Oncol, Nanning, Guangxi, Peoples R China[12]Hai Nan Gen Hosp Internal Med One, Med Oncol, Haikou, Hainan, Peoples R China[13]Canc Hosp Henan Prov, Med Oncol, Zhengzhou, Henan, Peoples R China内科第一医学部肿瘤内科河南省肿瘤医院[14]Chinese Acad Med Sci, Canc Hosp, Med Oncol, Beijing, Peoples R China[15]Peking Union Med Coll Hosp, Med Oncol, Beijing, Peoples R China[16]Fudan Univ, Shanghai Canc Ctr, Med Oncol, Shanghai, Peoples R China[17]Merck Serono, Med Oncol, Beijing, Peoples R China[18]Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou, Guangdong, Peoples R China临床科室内科中山大学肿瘤防治中心
第一作者机构:[1]Tongji Univ, Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China
推荐引用方式(GB/T 7714):
Guo Y.,Luo Y.,Zhang Q.,et al.First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial[J].ANNALS OF ONCOLOGY.2018,29:-.doi:10.1093/annonc/mdy483.005.
APA:
Guo, Y.,Luo, Y.,Zhang, Q.,Huang, X.,Li, Z....&Lin, T..(2018).First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial.ANNALS OF ONCOLOGY,29,
MLA:
Guo, Y.,et al."First-line cetuximab plus cisplatin and fluorouracil vs cisplatin and fluorouracil in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: The randomized, phase III CHANGE-2 trial".ANNALS OF ONCOLOGY 29.(2018):-